NASDAQ: PTGXProtagonist Therapeutics Inc Stock
$45.82+0.20 (+0.44%)
Updated Apr 30, 2025
PTGX Price
$45.82
Fair Value Price
N/A
Market Cap
$2.81B
52 Week Low
$25.23
52 Week High
$60.60
P/E
10.25x
P/B
4.17x
P/S
5.47x
PEG
N/A
Dividend Yield
N/A
Revenue
$434.43M
Earnings
$275.19M
Gross Margin
100%
Operating Margin
64.32%
Profit Margin
63.3%
Debt to Equity
0.1
Operating Cash Flow
$184M
Beta
1.17
Next Earnings
May 5, 2025
Ex-Dividend
N/A
Next Dividend
N/A
PTGX Overview
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PTGX's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
PTGX
Ranked#97 of 462
Ranked#97 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.07 | A | |
| $8.24 | A | |
| $24.29 | A |
Be the first to know about important PTGX news, forecast changes, insider trades & much more!
PTGX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PTGX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PTGX is good value based on its earnings relative to its share price (10.25x), compared to the US market average (29.18x)
P/E vs Market Valuation
PTGX is good value based on its earnings relative to its share price (10.25x), compared to the US Biotechnology industry average (-162.28x)
P/E vs Industry Valuation
PTGX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more PTGX due diligence checks available for Premium users.
Valuation
PTGX fair value
Fair Value of PTGX stock based on Discounted Cash Flow (DCF)
Price
$45.82
Fair Value
$1.33
Overvalued by
3,351.91%
PTGX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
10.25x
Industry
-162.28x
Market
29.18x
PTGX is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
PTGX is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
PTGX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.17x
Industry
4.45x
PTGX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PTGX's financial health
Profit margin
Revenue
$170.6M
Net Income
$131.7M
Profit Margin
77.2%
PTGX's Earnings (EBIT) of $279.41M... subscribe to Premium to read more.
Interest Coverage Financials
PTGX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$744.7M
Liabilities
$69.4M
Debt to equity
0.1
PTGX's short-term assets ($591.64M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PTGX's short-term assets ($591.64M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PTGX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
PTGX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$29.2M
Investing
-$8.7M
Financing
$4.0M
PTGX's operating cash flow ($184.15M)... subscribe to Premium to read more.
Debt Coverage Financials
PTGX vs Biotech Stocks
Protagonist Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.